drugset
Drugs / Ad26.ZEBOV/MVA-BN-Filo
last change Mar 2021 re-read 3 minutes ago

Ad26.ZEBOV/MVA-BN-Filo

Vaccine

Developed for
Ebola hemorrhagic fever
Investigated by
Coalition for Epidemic Preparedness Innovations · Epicentre, Mbarara, Uganda · Epicentre, Paris, France. · Janssen Pharmaceutica N.V., Belgium · MRC/UVRI and LSHTM Uganda Research Unit

Trials 1

today NCT04028349 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04028349 Aug 2019 → Mar 2021 Ebola hemorrhagic fever MRC/UVRI and LSHTM Uganda Research Unit Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Ad26.ZEBOV/MVA-BN-Filo ClinicalTrials.gov intervention name — accepted as the source's own label NCT04028349 ↗
Modality Vaccine “Candidate Ebola Vaccine” NCT04028349 ↗